Quessenberry Leads Texans Into Thursday Night Football

David Quessenberry, the 24-year-old offensive tackle for the Houston Texans currently battling non-Hodgkin's lymphoma, served as honorary captain for his team during Thursday Night Football.

Quessenberry not only led the Texans out of the tunnel and served as captain in the game against the Indianapolis Colts, but he also presented a check for $100,000 to the Lymphoma Research Foundation, money raised by fellow linemen Duane Brown and Chris Myers in the "DQ Strong" campaign.

Just being on his team's home field at game time meant a lot to the second-year player, telling the Houston Chronicle that it was "a way to show the city of Houston that I'm here and I'm fighting it and that your support really does affect me and really does motivate me to get through those hard days."

Just over half way finished with chemotherapy, Quessenberry will then begin radiation, and his treatment is right on track.

"Everything's going the way it should go," he told the Chronicle. "It's not too far advanced. It's not behind. It's right where it should go."

Diagnosed this past summer prior to the start of the season, Quessenberry missed his rookie season last year due to injury.

Source: Houston Chronicle

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap